Healthcare Business

How Biotech and Big Pharma Have Upside Heading Into Earnings

Biotech and many of the so-called Big Pharma have been duds in 2019. Despite many FDA approvals and some powerful mergers and royalty deals, the political pressure around drug pricing ...
Read Full Story »

A Crucial Major Depressive Disorder Study Is About to Be Underway

After Axsome Therapeutics Inc. (NASDAQ: AXSM) announced that it has completed patient enrollment in its Gemini study, a Phase 3 trial of AXS-05 in patients with major depressive disorder (MDD), ...
Read Full Story »

Are Shareholders Getting Enough in the Achillion Acquisition?

Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) shares skyrocketed on Wednesday morning after an announcement that the firm would be acquired by Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). While shares are up sharply ...
Read Full Story »

Why This Neuromuscular Disorder Study Could Be the Next Big Thing

Reata Pharmaceuticals Inc. (NASDAQ: RETA) shares jumped on Tuesday after the firm announced positive results from its midstage neuromuscular disorder drug trial. Specifically, the results are from Reata’s MOXIe Phase ...
Read Full Story »

Johnson & Johnson Offers a Strong Start to Earnings Season

When Johnson & Johnson (NYSE: JNJ) reported its most recent quarterly results before the markets opened on Tuesday, the pharmaceutical giant said it had $2.12 in earnings per share (EPS) ...
Read Full Story »

UnitedHealth Helps Save the Dow With Q3 Earnings

When UnitedHealth Group Inc. (NYSE: UNH) reported its third-quarter financial results before the markets opened on Tuesday, the Minnesota-based health care giant said that it had $3.88 in earnings per ...
Read Full Story »

What to Watch in the UnitedHealth Earnings Report Tuesday

UnitedHealth Group Inc. (NYSE: UNH) is set to release its third-quarter financial results before the markets open on Tuesday. Consensus estimates call for $3.75 in earnings per share (EPS) and ...
Read Full Story »

What to Expect When Johnson & Johnson Reports Tuesday

Johnson & Johnson (NYSE: JNJ) is scheduled to report its most recent quarterly results before the markets open on Tuesday. The consensus estimates are calling for $2.00 in earnings per ...
Read Full Story »

Are Allergan Shareholders Getting Enough in the AbbVie Acquisition?

Allergan PLC (NYSE: AGN) finally has announced that its shareholders have voted to approve the company’s acquisition by AbbVie Inc. (NYSE: ABBV). The acquisition is expected to close in early ...
Read Full Story »

New Osteoarthritis Treatment Has to Wait Even Longer for FDA Approval

Flexion Therapeutics Inc. (NASDAQ: FLXN) has announced that the U.S. Food and Drug Administration (FDA) informed the company that it needs additional time to complete the review of the supplemental ...
Read Full Story »

Are Shareholders Getting Enough From the Ra Pharma Acquisition?

Ra Pharmaceuticals Inc. (NASDAQ: RARX) shares more than doubled on Thursday after the announcement that UCB would acquire the firm. The boards of directors of both companies have unanimously approved ...
Read Full Story »

Short Sellers Hike Bets in Major Biotechs

The short interest data are out for the most recent settlement date, September 30. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Johnson & Johnson Has a Lot on Its Hands After $8 Billion Court Ruling

The announcement that a jury has awarded $8 billion in damages to a man accusing Johnson & Johnson (NYSE: JNJ) of failing to warn about the side effects of ...
Read Full Story »

SmileDirectClub Finally Has Something to Smile About

SmileDirectClub Inc. (NASDAQ: SDC) finally has something to smile about in the wake of its initial public offering, as shares made a handy gain early on Wednesday. The firm announced ...
Read Full Story »